May 2022 Issue | Blood Cancers Today

May 2022

This issue of Blood Cancers Today includes the latest updates on COVID-19 and hematologic malignancies, a debate on whether frontline myeloma treatment should include a monoclonal antibody, and more.

Viewpoints

Editor's Message

“Dude, We’re Getting the Band Back Together”

Perspectives

A Criticism of the Career Critics

Features

News

In the Literature

Phase III Trial Shows Ivosidenib Plus Azacitidine Provided Clinical Benefit in Patients with IDH1-Mutated AML

ZUMA-12 Trial Assesses Axicabtagene Ciloleucel as First-Line Therapy for High-Risk B-Cell Lymphoma

Regulatory Actions

FDA Approves CAR-T Therapy for Second-Line Treatment of Large B-Cell Lymphoma

FDA Panel Unanimously Recommends Randomized Data for PI3K Inhibitors in Hematologic Cancers

Gamma Delta CAR T-Cell Therapy Granted Fast Track Designation

FDA Puts Partial Hold on Study of Emavusertib in AML/MDS

PRGN-3006 UltraCAR-T Granted Fast Track Designation

State of the Art

Use of Frailty Scales in Patients with Myeloma Helps to Personalize Treatment

Editorial Board

Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine

Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center

Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center

Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch

Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer